These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16391848)

  • 21. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes.
    Azuma T; Otsuki T; Kuzushima K; Froelich CJ; Fujita S; Yasukawa M
    Clin Cancer Res; 2004 Nov; 10(21):7402-12. PubMed ID: 15534117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8.
    Kiessling A; Füssel S; Schmitz M; Stevanovic S; Meye A; Weigle B; Klenk U; Wirth MP; Rieber EP
    Prostate; 2003 Sep; 56(4):270-9. PubMed ID: 12858355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
    Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
    Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
    Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
    Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
    Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
    Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H
    Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients.
    Jin M; Komohara Y; Shichijo S; Harada M; Yamanaka R; Miyamoto S; Nikawa J; Itoh K; Yamada A
    Oncol Rep; 2008 May; 19(5):1277-83. PubMed ID: 18425388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients.
    Liu FF; Dong XY; Pang XW; Xing Q; Wang HC; Zhang HG; Li Y; Yin YH; Fant M; Ye YJ; Shen DH; Zhang Y; Wang S; Chen WF
    Gastroenterology; 2008 Apr; 134(4):998-1006. PubMed ID: 18395081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
    Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
    Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
    Wang Y; Takao Y; Harada M; Komatsu N; Ono T; Sata M; Itoh K; Yamada A
    Cell Immunol; 2006 May; 241(1):38-46. PubMed ID: 16963008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy.
    Carlsson B; Forsberg O; Bengtsson M; Tötterman TH; Essand M
    Prostate; 2007 Mar; 67(4):389-95. PubMed ID: 17219382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma.
    Wang Y; Harada M; Yano H; Ogasawara S; Takedatsu H; Arima Y; Matsueda S; Yamada A; Itoh K
    J Immunother; 2005; 28(6):535-41. PubMed ID: 16224270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.
    Hegde U; Chhabra A; Chattopadhyay S; Das R; Ray S; Chakraborty NG
    Pathobiology; 2008; 75(3):200-8. PubMed ID: 18550918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.